Korsana Biosciences, Inc. filed its Form 10-Q for the quarterly period ended September 30, 2026 with the U.S. Securities and Exchange Commission on November 5, 2026, reporting a net loss of $46.4 million for the third quarter and cash and cash equivalents of $456.2 million.

Key Highlights

  • Cash position: Cash and cash equivalents stood at $456,221 thousand as of September 30, 2026, up from $154,135 thousand at December 31, 2025.
  • Q3 net loss: The company reported a net loss of $46,425 thousand for the three months ended September 30, 2026, compared to $21,723 thousand for the same period in 2025.
  • Nine-month net loss: For the nine months ended September 30, 2026, the net loss totaled $77,295 thousand, versus $21,948 thousand for the nine months ended September 30, 2025.
  • R&D expenses: Research and development expenses were $42,139 thousand for Q3 2026 and $69,130 thousand for the nine months ended September 30, 2026.
  • Shares outstanding: As of November 2, 2026, the registrant had 45,541,358 shares of common stock outstanding.
  • Accumulated deficit: The accumulated deficit reached $113,025 thousand as of September 30, 2026, compared to $35,730 thousand at December 31, 2025.
  • Total assets: Total assets were $462,084 thousand as of September 30, 2026, versus $154,596 thousand at December 31, 2025.

Korsana Biosciences Reports Q3 2026 Financial Results and Balance Sheet Expansion

According to the filing, Korsana Biosciences, Inc. (NASDAQ:KRSA), a Massachusetts-incorporated biosciences company headquartered in Waltham, MA, reported a significant increase in both cash on hand and operating losses for the three and nine months ended September 30, 2026. Total operating expenses for Q3 2026 were $48,274 thousand, driven primarily by research and development costs of $42,139 thousand and general and administrative expenses of $6,135 thousand, the company disclosed.

The filing noted that related-party amounts included in research and development expenses were $23,662 thousand for the three months ended September 30, 2026 and $39,849 thousand for the nine months ended September 30, 2026. Interest income of $1,849 thousand for Q3 2026 partially offset operating losses, bringing the net loss for the quarter to $46,425 thousand. The net loss per share attributable to common stockholders, basic and diluted, was $(3.19) for Q3 2026, compared to $(39.49) for Q3 2025, reflecting the significantly higher weighted-average share count of 13,525,610 versus 550,061 in the prior-year period.

On the balance sheet, the company reported total stockholders' equity of $391,563 thousand as of September 30, 2026, a reversal from a deficit of $33,968 thousand at December 31, 2025. The filing also disclosed 4,148 shares of Series B non-voting convertible preferred stock issued and outstanding as of September 30, 2026, with a carrying amount of $24,964 thousand, while all previously outstanding Series Seed and Series A convertible preferred stock had been converted, leaving no shares of those series outstanding as of September 30, 2026, according to the filing.

What Was Disclosed

Korsana Biosciences filed its unaudited quarterly report covering the period ended September 30, 2026, disclosing a net loss of $46,425 thousand for Q3, cash of $456,221 thousand, an accumulated deficit of $113,025 thousand, and 45,541,358 common shares outstanding as of November 2, 2026.